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OBJECTIVE: To investigate the value of high-flow nasal cannula oxygen therapy after extubation in patients
with acute respiratory failure.
METHODS: A single-center, prospective, randomized, controlled pilot trial was conducted between January
2013 and December 2014. Sixty enrolled patients were randomized immediately after extubation into either a
high-flow nasal cannula group (n=30) or an air entrainment mask group (n=30) at a fixed inspired oxygen
fraction (40%). The success rate of oxygen therapy, respiratory and hemodynamic parameters and subjective
discomfort (using a visual analogue scale) were assessed at 24h after extubation.
RESULTS: The two groups were comparable at extubation. A total of 46 patients were successfully treated
including 27 patients in the high-flow nasal cannula group and 19 patients in the air entrainment mask group.
Compared to the air entrainment mask group, the success rate of oxygen therapy and the partial pressure of
arterial oxygen were significantly higher and the respiratory rate was lower in the high-flow nasal cannula
group. In addition, less discomfort related to interface displacement and airway dryness was observed in the
high-flow nasal cannula group than in the air entrainment mask group.
CONCLUSIONS: At a fixed inspired oxygen fraction, the application of a high-flow nasal cannula after
extubation achieves a higher success rate of oxygen therapy and less discomfort at 24h than an air entrainment
mask in patients with acute respiratory failure.
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’ INTRODUCTION
Acute respiratory failure (ARF) is the most common cause
of admission to the intensive care unit (ICU) and often req-
uires endotracheal intubation and mechanical ventilation (1).
After improvements, these ventilated ARF patients should be
considered for weaning and extubation. However, extuba-
tion remains a challenge in the critical care field, as a high
reintubation rate exists (19%) (2). Patients are still patho-
physiologically unstable after extubation, with symptoms
such as incomplete recovery of primary diseases, oxygen
deficit, upper airway obstruction, excess respiratory secre-
tions, inadequate cough, or respiratory muscle weakness (3).
Oxygen therapy is crucial to maintain the oxygen demand and
to prevent the recurrence of ARF. A variety of conventional
oxygen therapy (COT) systems that are classified as either
fixed or variable performance are available, with various
limitations (4). The air entrainment mask, as a fixed type, can
increase dryness of the respiratory tract, influence daily
patient activity, and cause patient discomfort. In addition,
a nasal cannula cannot provide a constant oxygen concentra-
tion. Meanwhile, noninvasive ventilation (NIV) might not be
suitable for all extubated patients due to their poor tolerance
and cooperation (5).
Recently, the high-flow nasal cannula (HFNC) oxygen
system (Optiflow, Fisher & Paykel Healthcare, Auckland,
New Zealand), delivering heated and humidified high-
flow (up to 60 L/min) gas, was introduced and has become
widely used in clinical practice (6). It has several advantages,
such as efficient humidification and airway mucociliary
clearance, accurate fraction of inspired oxygen (FiO2) deli-
very and a low-level positive airway pressure (7). The con-
cept of HFNC initially originated from the treatment ofDOI: 10.6061/clinics/2017(09)07
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preterm infants as an alternative to nasal continuous positive
airway pressure (CPAP) (8). The feasibility, efficacy, and
tolerance of the HFNC have been tested in neonatal and
pediatric care (9). More recently, the HFNC has been widely
used in adults with hypoxemic ARF of different etiologies
(10), in do-not-intubate patients (11), after cardiac surgery
(12), in invasive practices such as bronchoscopy (13) and in
other applications. Compared to COT, the HFNC can enhance
patient comfort and tolerance, improve oxygenation, and
reduce the reintubation rate (14,15). However, in some cases,
the HFNC did not improve oxygenation or reduce the need
for escalation of respiratory support (16). Thus, the exact
efficacy of HFNC is still controversial or uncertain. Two recent
randomized clinical trials have shown that use of an HFNC
after extubation can decrease the need for reintubation
compared with COT (15) and is not inferior to NIV for pre-
venting reintubation and postextubation respiratory failure
(17). However, in these two studies, the FiO2 was adjustable,
and the studies included patients who were at either low risk
(15) or high risk for reintubation (17).
Given that the HFNC has the intrinsic advantages of effi-
cient humidification and dynamic positive airway pressure
(7), we hypothesized that at a fixed FiO2 and use of an HFNC
after extubation could achieve a higher success rate of oxy-
gen therapy than an air entrainment mask in ARF patients.
’ MATERIALS AND METHODS
This study was approved by the Ethics Committee of Hain-
ing People’s Hospital, Zhejiang, China. Written informed
consent was obtained from included patients or their sur-
rogates. Mechanically ventilated ARF patients who were
admitted to the 24-bed adult comprehensive ICU at Haining
People’s Hospital between January 2013 and December 2014
were prospectively included. The criteria for ARF were based
on the conventional definition: partial pressure of arterial
oxygen (PaO2) o60 mmHg, partial pressure of arterial car-
bon dioxide (PaCO2)445 mmHg, or both (18). Patients were
included in this study if they had undergone mechanical
ventilation for at least 48h and were ready for tracheal extu-
bation after clinical weaning assessments, according to the
international consensus conference on weaning (19); the criteria
for weaning assessments in this study included evidence of
clinical improvement of the original pathologic process leading
to ARF, relative cardiovascular stability with (at most) a mini-
mum requirement for vasopressors, adequate mentation, efforts
at spontaneous ventilation, and adequate oxygenation (defined
as a PaO2/FiO2 of at least 150 mmHg with FiO2p0.4 and
PEEPp8 cmH2O). Patients were excluded from this study if
they had poor cooperation, a tracheostomy, or a decreased level
of consciousness (Glasgow Coma Scale score of 12 points or
less); were younger than 18 years old or pregnant; or did not
sign the informed consent form.
The patients who met the weaning criteria and success-
fully passed the spontaneous breathing trial with 7 cmH2O
of pressure support for 30 to 120 min were eligible and ready
for tracheal extubation. The baseline time point was defined
as the end of the spontaneous breathing test and immedi-
ately before extubation. Immediately after extubation, the
patients were randomized into two groups: oxygen treat-
ment by HFNC (PT101AZ, Fisher & Paykel Healthcare,
Auckland, New Zealand) or air entrainment mask (Jinlin
Medical Appliances Factory, Hangzhou, China). Randomiza-
tion was accomplished using a computer-generated random
number sequence. In both groups, the FiO2 was set at 40%.
The flow level of the HFNC began at 60 L/min and was
adjusted downward in 5- to 10-L/min decrements as the
target oxygenation improved or stabilized, while the flow
rate of the air entrainment mask was set at 10 L/min.
The target oxygenation in our study was a pulse oxygen
saturation (SpO2) of 94–98% for most patients (hypoxic
respiratory failure) or 88–92% for those with hypercapnic
respiratory failure. Demographic data such as age, gen-
der, and Acute Physiology and Chronic Health Evaluation II
(APACHE-II) score were recorded at baseline. Electrocardio-
graphy variables, heart rate, blood pressure, mean arterial
pressure, respiratory rate, SpO2, and arterial blood gas values
were monitored at baseline and 24h after extubation. A visual
analog scale (20) [from 0 (no discomfort) to 10 (maximum
discomfort)] was used to assess patient discomfort related to
airway dryness or the interface. In addition, adverse events,
including replacement of the original oxygen system (shifting
to an HFNC from the air entrainment mask in this study) and
requiring NIV or endotracheal intubation, were also recorded.
Decisions to apply NIVor endotracheal intubation were based
on previous criteria (21,22). The ventilator mode of NIV was
set to pressure support mode or pressure controlled mode.
The criteria for shifting to an HFNC from the air entrainment
mask were based on a previous study (23) and were modified
as follows: respiratory rate430 breaths/min, SpO2o90%, or
intolerance to the air entrainment mask. The primary objective
of this study was to evaluate the success rate of oxygen
therapy at 24h after extubation. In the present study, successful
oxygen therapy was defined as not requiring a replacement
oxygen device, NIV, or reintubation within 24h after extuba-
tion. The secondary objectives of the study were to investigate
respiratory variables, hemodynamic variables, and patient
discomfort at 24h after extubation.
The results of this study were presented as absolute num-
bers and percentages or means and standard deviations for
continuous data if normally distributed and medians and
ranges if not normally distributed. Comparisons between the
two groups were performed using a t test or Mann-Whitney
U test for metric data and the chi-square test for categorical
data. A two-sided p-value of less than 0.05 was considered
significant. IBM SPSS Statistics for Windows software (IBM
Corp. Released 2011. Version 20.0. Armonk, NY, USA) was
used for data analysis.
’ RESULTS
Between January 2013 and December 2014, 68 patients met
the inclusion criteria and were eligible to participate in this
study (flow chart in Figure 1). Eight patients were excluded
from the study: three patients declined informed consent,
two patients removed invasive arterial monitoring catheters
during the study period, and three other patients were tran-
sferred out of the ICU on the day of extubation. Eventually,
30 patients were included in the HFNC group, and 30 patients
were included in the air entrainment mask group. The demo-
graphic and clinical characteristics of the two groups at
baseline were comparable, as shown in Table 1.
Among the 60 patients, 46 were successfully treated by
initial oxygen therapy within 24h after extubation, including
27 in the HFNC group and 19 in the air entrainment mask
group. The success rate of oxygen therapy by HFNC (27/30,
90%) was significantly higher than that by the air entrain-
ment mask (19/30, 63.3%) (p=0.01) (Table 2). Of the 11 patients
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who failed treatment with the air entrainment mask, 3
received NIV, 3 required reintubation, and 5 were shifted to
the HFNC (these patients were all successfully treated by
HFNC). Although no significant difference was found, the rate
of ventilator support (3/30, 10%) in the HFNC group was
lower than that in the air entrainment mask group (6/30,
20%). A total of four patients required reintubation: one in the
HFNC group (1/30, 3.33%) and three in the air entrainment
mask group (3/30, 10%); the difference was not statistically
significant (Table 2).
At 24 h after extubation, the average flow rate in the
HFNC group was 36.8±2.8 L/min. In addition, the HFNC
significantly improved the PaO2 and SpO2 at 24h after
extubation compared to the air entrainment mask (83.2±
10.5 mmHg vs. 74.5±13.1 mmHg, p=0.016; 98.0±1.3% vs.
96.9±1.4%, p=0.011, respectively). The PaCO2 values were
similar between the two groups (p=0.591, Table 2). The res-
piratory rate was significantly lower for the HFNC group than
for the air entrainment mask group (22±3.6 breaths/min vs.
26±4.3 breaths/min, p=0.003). No significant differences in
Figure 1 - Flow diagram of participants enrolled in the study and associated clinical outcomes after extubation.ICU: Intensive care unit;
HFNC: high-flow nasal cannula; NIV: noninvasive ventilation; IV: invasive ventilation.
Table 1 - Baseline patient characteristics.
HFNC (n=30) Air entrainment mask (n=30)
Male, n (%) 116 (53.3) 18 (60)
Age, years 66±14 71±13
APACHE-II 12.87±3.0 12.36±3.29
Causes of ARF, n (%)
Pneumonia 12 (40) 13 (43.3)
COPD exacerbation 7 (23.3) 6 (20)
Cardiogenic pulmonary edema 5 (16.7) 6 (20)
Multiple trauma 1 (3.3) 2 (6.7)
Cardiac arrest 2 (6.7) 1 (3.3)
Others* 3 (10) 2 (6.7)
Length of MV before inclusion (days) 5.5±3.4 5.4±2.8
Heart rate (beats/min) 82.80±9.85 81.53±8.92
Mean arterial pressure (mmHg) 83±9 83±10
PaCO2 (mmHg) 41.5±6.7 42.3±7.1
PaO2 (mmHg) 82.8±11.0 81.7±11.6
SpO2 (%) 96.2±2.3 95.1±2.9
*Others included psychiatric drug poisoning (n=1), severe acidosis (n=3), and epileptic seizures (n=1).
HFNC: High-flow nasal cannula; APACHE-II: Acute Physiology and Chronic Health Evaluation II score; ARF: Acute respiratory failure; COPD: Chronic
obstructive pulmonary disease; MV: Mechanical ventilation.
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heart rate and mean arterial pressure were observed between
the two groups (Table 2).
Discomforts related to the interface and symptoms of
airway dryness were significantly lower in the HFNC group
than those in the air entrainment mask group [3(3-4.5) vs.
7(6-8); 3(2-3.5) vs. 5(4.7-6), both po0.001] (Figure 2).
’ DISCUSSION
The main findings of this study were as follows: after
extubation of mechanically ventilated ARF patients, the
application of an HFNC achieved a higher success rate of
oxygen therapy within 24 h than the air entrainment mask.
In addition, use of the HFNC resulted in improved oxy-
genation, a decreased respiratory rate, and reduced patient
discomfort compared to the air entrainment mask. After
failure with the air entrainment mask, five patients were
shifted to the HFNC group and ultimately achieved success
with oxygen therapy, thus avoiding the introduction of
NIV or reintubation. Consistent with other studies (14,15),
our study also confirmed that the HFNC is a promising
oxygen therapy device for patients with ARF after extuba-
tion. Moreover, this procedure could even be used as an
alternative after the failure of other oxygen devices to reduce
the need for NIV or reintubation; these findings indirectly
supported the conclusion obtained by Hernández et al. (17),
namely, that HFNC was not inferior to NIV in terms of
reintubation or postextubation failure.
The HFNC has been increasingly used in patients after
extubation, although its efficacy remains unclear. Tiruvoipati
et al. (24) showed that the HFNC was better tolerated than
a high-flow face mask in 50 extubated patients, despite a
similar effectiveness of oxygen delivery. In 2014, Rittayamai
et al. (25) found that the HFNC improved dyspnea and the
respiratory and heart rates compared to a non-rebreathing
mask in 17 extubated patients. However, these two studies
observed only the short-term efficacy of the HFNC (24,25).
The relative long-term efficacy of the HFNC in extuba-
ted patients was investigated in two recent well-designed
studies (14,15). Maggiore et al. (14) found that HFNC oxygen
therapy resulted in significantly better oxygenation, better
comfort, and a lower reintubation rate (3.8%) during the 48-h
study period than COT in 105 critically ill patients. Similarly,
Hernández et al. (15) also showed that HFNC application
resulted in a significantly lower reintubation rate (4.9%) than
COT (12.2%) within 72 h in 527 adult patients at low risk for
reintubation. However, the influence of the FiO2 on the
efficacy of the HFNC for oxygen therapy was not excluded in
these two studies. Our study extended the application of the
HFNC to use in patients after extubation, even for those with
a fixed FiO2.
The exact mechanism of the beneficial effects observed
from the application of the HFNC remains unclear. The
following factors should be considered. (a) The high-flow
oxygen (up to 60 L/min) delivered by the HFNC meets or
exceeds the patient’s peak inspiratory demand, which might
deliver a more accurate FiO2 with a fixed FiO2. (b) The
delivery of high-flow oxygen flushes the anatomical dead
space of the upper airway, creating a reservoir of fresh gas
available for every breath to minimize re-breathing of CO2,
which would improve the efficiency of ventilation and
oxygen delivery. The PaCO2 level at 24 h after oxygen the-
rapy was similar between the two groups, which suggested
that the HFNC had no significant effect on the PaCO2 values
in our study. (c) In contrast to COT, the HFNC system can
generate positive airway pressure to increase airway com-
pliance and reduce the breathing work (26). (d) The suf-
ficiently heated humidified air produced by the HFNC
facilitates secretion clearance and decreases bronchial hyper-
response symptoms (27). (e) Better subjective comfort
generally results in better subject compliance and a better
outcome (28). Our study confirmed that HFNC oxygen
therapy led to reduced patient discomfort compared to the
Table 2 - Primary and secondary outcomes in the two treatment groups.
HFNC Air entrainment mask p
Primary outcomes n=30 n=30
Success rate of oxygen therapy 27/30 (90%) 19/30 (63.33%) 0.012
NIV 2 (6.67%) 3 (10%) 0.639
Endotracheal intubation 1 (3.33%) 3 (10%) 0.290
Replacement of oxygen device 0 (0%) 5 (16.67%) 0.062
Secondary outcomes n=27 n=19
PaO2 (mmHg) 83.2±10.5 74.5±13.1 0.016
SpO2 (%) 98.0±1.3 96.9±1.4 0.011
PaCO2 (mmHg) 41.4±6.5 42.2±13.1 0.591
Respiratory rate (breaths/min) 22±4 26±4 0.003
Heart rate (beats/min) 85±9 87±14 0.598
Mean arterial pressure (mmHg) 85±8 86±9 0.824
HFNC: High-flow nasal cannula; NIV: Noninvasive ventilation.
Figure 2 - High-flow nasal cannula (HFNC) oxygen therapy
improved the discomforts related to the interface and symptoms
of airway dryness compared to the air entrainment mask.
Patients’ discomforts were assessed by scores related to the
interface (panel A) or airway dryness (panel B) via a visual analog
scale [from 0 (no discomfort) to 10 (maximum discomfort)]
(*po0.001 compared to the air entrainment mask).
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air entrainment mask. We also showed that the rate of
ventilatory support (NIV or reintubation) in the air entrain-
ment mask group tended to be higher than that in the HFNC
group, and this trend might be associated with the mis-
match between the oxygen flow and the patient’s inspiratory
demand, the patients’ intolerance to the mask, the instability
of the delivered FiO2, and/or insufficiency of heating and
humidification (4,7). An oxygen target (a SpO2 of 94–98% for
most patients) and a fixed FiO2 of 40% were set in the present
study, which could raise the question of how to improve
oxygenation. Indeed, we performed other measures, such as
maintenance of a high flow rate and/or sputum removal;
NIVand reintubation were also considered if necessary. Most
patients in the current study met the target oxygenation at a
fixed FiO2 of 40%, and only 6.67% (4/60) required reintuba-
tion, mainly due to respiratory muscle weakness, cardiac fai-
lure, excess respiratory secretions, and/or changes in mental
status.
Our study has several limitations. (a) The small number
of patients and the pilot study design resulted in a rela-
tively low statistical power. Based on a superior design
according to the acute sample size using SAS software
(Cary, North Carolina USA), the sample size of 30 in each
group would have a power of 0.807, with a level of sig-
nificance of 0.05 (the success rates of oxygen therapy were
90% and 63% in the HFNC and air entrainment mask groups,
respectively) (Table 2). (b) In this study, we considered the
5 patients with successful shifts to the HFNC oxygen treat-
ment as treatment failures to their initial oxygen therapy
by air entrainment mask (Figure 1). To some extent, it might
be reasonable to crossover these 5 patients because this
finding further suggests that HFNC oxygen treatment might
be superior to use of an air entrainment mask. As this study
was open label by nature, it was difficult to blind partic-
ipants and clinicians to the allocated oxygen therapy, which
is a problem inherent to many studies of medical devices.
This problem was relatively weakened by the randomization
techniques and the comparability of the groups at baseline in
the current study. (c) The APACHE-II scores in both groups
were approximately 12; thus, the severity of the population
in this study was relatively minor. Whether HFNC therapy is
suitable for more serious patients with respiratory failure
after extubation requires further investigation. (d) Although
a fixed FiO2 setting was used in both groups in our study, the
actual FiO2 delivered to the patient might be inconsistent
with the set FiO2 in some cases. For example, the actual FiO2
delivered to the patient could be lower than 40% with both
the air entrainment mask (in case of a higher respiratory rate
or tidal volume) and the HFNC (when lower flow rates were
used while the patient’s peak inspiratory flow was higher).
The use of greater flow rates with the HFNC could allow
more stable delivery of the FiO2. Unfortunately, we did not
measure the actual FiO2 delivered to the patient. (e) The
potential beneficial effects of the HFNC on sputum clearance
and bronchial hyper-response symptoms were not assessed,
which might also contribute to the higher success rate of
initial oxygen treatment by improving mucociliary function
and reducing the work of breathing. (f) The assessment of
patient discomfort was subjective. However, this method is
widely used in the measurement of breathlessness and other
symptoms (20). (g) Indeed, we also clinically titrated the
amount of oxygen according to the patients’ needs, but not
with a fixed FiO2. However, the aim of the current study was
to investigate whether the potential mechanisms underlying
the benefit of HFNC oxygen treatment were unrelated to the
amount of oxygen, and we used a fixed FiO2.
In summary, HFNC oxygen therapy after extubation in
mechanically ventilated ARF patients can achieve a higher
success rate of oxygen therapy, improved oxygenation, and a
lower occurrence of discomfort than an air entrainment mask.
Thus, HFNC oxygen therapy might be a promising treatment
for ARF patients after extubation.
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